CHICAGO (EGMN) - The need to reassess the biology of breast cancer after it progresses was driven home in three studies described as the largest to date to tackle the issue of hormone receptor discordance.Smaller, mostly retrospective studies using varying methodology to evaluate receptor status have reported discordance between the primary tumor and progressive disease ranging from 18% to 55%. Some have suggested that discordance may be associated with poorer survival due in part to inappropriate...